CXCR4 and rectal carcinoma: In rectal carcinoma cells, upregulation of CXCR4 was observed following anti-VEGF antibody treatment [32] and, recently, rituximab was shown to induce upregulation in Burkitt lymphoma cell lines and primary DLBCL cells [19].